Figueroa-Casas Pedro R
Universidad Nacional de Rosario.
Rev Fac Cien Med Univ Nac Cordoba. 2005;62(2 Suppl 1):32-6.
Starting from prospective clinical studies that have evaluated its benefits and risks, hormone replacement therapy in menopause women has been reassessed in its indications in the last four years. In October, 2004 a Latinamerican Experts Consensus was carried out, such report with some modifications is presented in this publication. The conclusions the experts reached were the following: 1) Hormone Therapy is the gold standard for the control of moderate to severe vasomotor symptoms; 2) this therapy must be indicated in an individual manner and only in symptomatic women in which the benefit is greater than the risk; 3) the least effective dose must be used; 4) it must be used neither for cardiovascular prevention, osteoporosis, colon cancer nor for mental disorder; 5) the patient must be informed about the benefits and risks.
从评估过其益处和风险的前瞻性临床研究出发，更年期女性的激素替代疗法在过去四年里其适应症已被重新评估。2004年10月开展了一项拉丁美洲专家共识会议，本出版物中呈现的是经过一些修改后的该报告。专家们得出的结论如下：1）激素疗法是控制中度至重度血管舒缩症状的金标准；2）这种疗法必须以个体化方式应用，且仅适用于那些益处大于风险的有症状女性；3）必须使用最低有效剂量；4）它既不能用于心血管疾病预防、骨质疏松症、结肠癌，也不能用于精神障碍；5）必须告知患者其益处和风险。
